Exchange / Market
Adocia specializes in the research and development of biotherapy products used in tissue regeneration and for treating chronic diseases.
At the end of June 2011, the group had a portfolio of 4 products in clinical development (including two in phase 2; PDGF-BB, for treating diabetic foot ulcers, and HinsBet, quick-acting human insulin for treating diabetes).
Initial Public Offering
Initial Public offering
LISTING DATE: 14/02/2012
TRADING DATE: 20/02/2012
Indicative price range for the Offer: EUR 13.00 - EUR 15.88 ("The Offering Price")